ADARx Pharmaceuticals disclosed plans for an IPO after filing with the SEC, positioning the San Diego RNA interference company to raise capital to support three drugs currently in the clinic. The filing highlights continued investor appetite for RNA platforms, while also underscoring how biotechs are timing public-market moves to ride broader issuance momentum.